Milestone Alert: R2 Technologies Ships Out 100 GLACIAL Rx Devices

GLACIAL Rx is the first-to-market controlled cooling treatment to temporarily reduce inflammation, pain, swelling, and to remove benign lesions. 

R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe.  

To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this milestone within its first year of commercial sales of the GLACIAL Rx platform.

GLACIAL Rx is the first-to-market controlled cooling treatment of its kind, FDA-cleared to temporarily reduce inflammation, pain, swelling, and to remove benign lesions.  GLACIAL Rx CryoAesthetic treatments can be delivered with or without topicals.

"We are thrilled to see U.S. customers and patients responding positively to the GLACIAL Rx platform, and it is quite an achievement to have reached this milestone within our first commercial sales year while launching during the pandemic," says Tim Holt, R2's Chief Executive Officer, in a news release. "We are grateful to the early adopters who have brought on GLACIAL Rx as a premium facial treatment and are exploring innovative ways to use GLACIAL contact cooling to reduce inflammation."

"I am thrilled to be part of the growing group of providers who offer GLACIAL Rx, as my patients tell me the only thing better than how the treatment feels, is how it makes their skin look," says Dr. Bruce Katz, board-certified dermatologist, and director of JUVA Skin & Laser Center. "Other devices can give you an immediate glow, but GLACIAL Rx clears up congestion and skin dullness immediately, but what really differentiates it, is that in the weeks following a treatment, the appearance of skin conditions such as age spots and redness or inflammation continue to improve."

In 2019, R2 brought on strategic partner, Huadong Medicine Co., Ltd. In close collaboration with these partners and the brand's scientific founders and Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers. Since inception, R2 has raised $76 million in financing led by a world-class team of experts within the aesthetics industry

Stay tuned for an in-depth article on this technology in an upcoming issue of our sister publication Modern Aesthetics® magazine.